Eli Lilly’s once-weekly basal insulin pen, Onswik, received FDA approval for patients with type 2 diabetes, setting up direct competition with Novo Nordisk. Lilly positioned the therapy as a longer-acting alternative to daily basal injections, aiming to simplify dosing for chronic glycemic control. The approval adds another practical dosing option for payers and clinicians, while raising competitive stakes for manufacturers already contesting long-acting insulin utilization and formulary placement. The move also signals ongoing regulatory comfort with incremental advances framed around convenience and pharmacologic duration. For biotech watchers, the decision highlights how next-generation insulin delivery—once-weekly regimens—remains a key battleground in established metabolic franchises.